David Scott, Ph.D., is Vice President, Medical and Scientific Affairs, Neuroscience at Clario. His aim is to facilitate drug development through standardized measurement of the neural correlates of neurodegenerative and other centrally mediated diseases. As a student at Johns Hopkins University and the University of Michigan, he employed multi-modal imaging approaches including dynamic PET and functional MRI to study the neurobiology of placebo analgesia. At Omneuron, he developed real-time fMRI applications aimed at treating chronic pain, depression and addiction. Since joining Clario in 2012, David’s focus has been to enable MRI and molecular imaging solutions toward safety, eligibility, and therapeutic efficacy endpoints. He works with radiologists, physicists, software engineers, and operational specialists on the design, execution, analysis, and interpretation of neuroscience clinical trial imaging data. His motivation is to enable neuroimaging to accelerate the delivery of therapeutic benefit to patients around the world.